Valneva says early studies show COVID-19 vaccine effective against Omicron

Valneva targets 2022 revenue boost on COVID-19 vaccine

[ad_1] The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner Register now for FREE unlimited access to Reuters.com Register Feb 3 (Reuters) – French vaccine developer Valneva (VLS.PA) expects its COVID-19 vaccine candidate to considerably boost its yearly sales in 2022, after they already […]

Continue Reading
Valneva says early studies show COVID-19 vaccine effective against Omicron

Valneva says early studies show COVID-19 vaccine effective against Omicron

[ad_1] The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner Register now for FREE unlimited access to Reuters.com Register Jan 19 (Reuters) – French biotech firm Valneva (VLS.PA) said on Wednesday that preliminary studies showed that three doses of its inactivated COVID-19 vaccine candidate […]

Continue Reading